Pérez-Ibarbia Leire, Majdanski Tobias, Schubert Stephanie, Windhab Norbert, Schubert Ulrich S
Evonik Nutrition & Care GmbH, Kirschenallee, 64293 Darmstadt, Germany.
Laboratory of Organic and Macromolecular Chemistry (IOMC), Friedrich Schiller University Jena, Humboldtstrasse 10, 07743 Jena, Germany; Jena Center for Soft Matter (JCSM), Friedrich Schiller University Jena, Philosophenweg 7, 07743 Jena, Germany.
Eur J Pharm Sci. 2016 Oct 10;93:264-73. doi: 10.1016/j.ejps.2016.08.026. Epub 2016 Aug 12.
Color selection is one of the key elements of building a strong brand development and product identity in the pharmaceutical industry, besides to prevent counterfeiting. Moreover, colored pharmaceutical dosage forms may increase patient compliance and therapy enhancement. Although most synthetic dyes are classified as safe, their regulations are stricter than other classes of excipients. Safety concerns have increased during the last years but the efforts to change to natural dyes seem to be not promising. Their instability problems and the development of "non-toxic" dyes is still a challenge. This review focuses specifically on the issues related to dye selection and summarizes the current regulatory status. A deep awareness of toxicological data based on the public domain, making sure the compliance of standards for regulation and safety for successful product development is provided. In addition, synthetic strategies are provided to covalently bind dyes on polymers to possibly overcome toxicity issues.
除了防止假冒外,颜色选择是制药行业建立强大品牌发展和产品标识的关键要素之一。此外,有颜色的药物剂型可能会提高患者的依从性并增强治疗效果。尽管大多数合成染料被归类为安全物质,但对它们的监管比对其他辅料类别更为严格。在过去几年中,安全问题日益增加,但转向天然染料的努力似乎并不乐观。它们的稳定性问题以及“无毒”染料的开发仍然是一个挑战。本综述特别关注与染料选择相关的问题,并总结了当前的监管状况。基于公共领域提供了对毒理学数据的深入认识,以确保符合法规标准和安全要求,从而实现成功的产品开发。此外,还提供了将染料共价结合到聚合物上的合成策略,以可能克服毒性问题。